Zhi-Feng Zhang1,2, Juan Chen1,3, Xin Han4, Ya Zhang1, Hua-Bao Liao1, Rui-Xue Lei1, Yang Zhuang1, Ze-Fen Wang1, Zhiqiang Li5, Jin-Cao Chen5, Wei-Jing Liao5, Hai-Bing Zhou4, Fang Liu6, Qi Wan1,5. 1. Department of Physiology, Collaborative Innovation Center for Brain Science, School of Basic Medical Sciences, Wuhan University School of Medicine, Wuhan, China. 2. Department of Physiology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China. 3. Department of Neurology, the Central Hospital of Wuhan, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China. 4. School of Pharmacy, Wuhan University, Wuhan, China. 5. Brain Centre, Zhongnan Hospital, Wuhan University School of Medicine, Wuhan, China. 6. Campbell Research Institute, Centre for Addiction and Mental Health, and Departments of Psychiatry, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND AND PURPOSE: We and others have shown that inhibiting phosphatase and tensin homolog deleted on chromosome 10 (PTEN) or activating ERK1/2 confer neuroprotection. As bisperoxovanadium compounds are well-established inhibitors of PTEN, we designed bisperoxovandium (pyridin-2-squaramide) [bpV(pis)] and determined whether and how bpV(pis) exerts a neuroprotective effect in cerebral ischaemia-reperfusion injury. EXPERIMENTAL APPROACH: Malachite green-based phosphatase assay was used to measure PTEN activity. A western blot assay was used to measure the phosphorylation level of Akt and ERK1/2 (p-Akt and p-ERK1/2). Oxygen-glucose deprivation (OGD) was used to injure cultured cortical neurons. Cell death and viability were assessed by LDH and MTT assays. To verify the effects of bpV(pis) in vivo, Sprague-Dawley rats were subjected to middle cerebral artery occlusion, and brain infarct volume was measured and neurological function tests performed. KEY RESULTS: bpV(pis) inhibited PTEN activity and increased p-Akt in SH-SY5Y cells but not in PTEN-deleted U251 cells. bpV(pis) also elevated p-ERK1/2 in both SH-SY5Y and U251 cells. These data indicate that bpV(pis) enhances Akt activation through PTEN inhibition but increases ERK1/2 activation independently of PTEN signalling. bpV(pis) prevented OGD-induced neuronal death in vitro and reduced brain infarct volume and promoted functional recovery in stroke animals. This neuroprotective effect of bpV(pis) was blocked by inhibiting Akt and/or ERK1/2. CONCLUSIONS AND IMPLICATIONS: bpV(pis) confers neuroprotection in OGD-induced injury in vitro and in cerebral ischaemia in vivo by suppressing PTEN and activating ERK1/2. Thus, bpV(pis) is a bi-target neuroprotectant that may be developed as a drug candidate for stroke treatment.
BACKGROUND AND PURPOSE: We and others have shown that inhibiting phosphatase and tensin homolog deleted on chromosome 10 (PTEN) or activating ERK1/2 confer neuroprotection. As bisperoxovanadium compounds are well-established inhibitors of PTEN, we designed bisperoxovandium (pyridin-2-squaramide) [bpV(pis)] and determined whether and how bpV(pis) exerts a neuroprotective effect in cerebral ischaemia-reperfusion injury. EXPERIMENTAL APPROACH: Malachite green-based phosphatase assay was used to measure PTEN activity. A western blot assay was used to measure the phosphorylation level of Akt and ERK1/2 (p-Akt and p-ERK1/2). Oxygen-glucose deprivation (OGD) was used to injure cultured cortical neurons. Cell death and viability were assessed by LDH and MTT assays. To verify the effects of bpV(pis) in vivo, Sprague-Dawley rats were subjected to middle cerebral artery occlusion, and brain infarct volume was measured and neurological function tests performed. KEY RESULTS:bpV(pis) inhibited PTEN activity and increased p-Akt in SH-SY5Y cells but not in PTEN-deleted U251 cells. bpV(pis) also elevated p-ERK1/2 in both SH-SY5Y and U251 cells. These data indicate that bpV(pis) enhances Akt activation through PTEN inhibition but increases ERK1/2 activation independently of PTEN signalling. bpV(pis) prevented OGD-induced neuronal death in vitro and reduced brain infarct volume and promoted functional recovery in stroke animals. This neuroprotective effect of bpV(pis) was blocked by inhibiting Akt and/or ERK1/2. CONCLUSIONS AND IMPLICATIONS: bpV(pis) confers neuroprotection in OGD-induced injury in vitro and in cerebral ischaemia in vivo by suppressing PTEN and activating ERK1/2. Thus, bpV(pis) is a bi-target neuroprotectant that may be developed as a drug candidate for stroke treatment.
Authors: Yosuke Ohtake; Dongsun Park; P M Abdul-Muneer; Hui Li; Bin Xu; Kartavya Sharma; George M Smith; Michael E Selzer; Shuxin Li Journal: Biomaterials Date: 2014-03-12 Impact factor: 12.479
Authors: Mihaela A Stavarache; Sergei Musatov; Marlon McGill; Mary Vernov; Michael G Kaplitt Journal: Neurobiol Dis Date: 2015-07-29 Impact factor: 5.996
Authors: Michael E Sughrue; J Mocco; Ricardo J Komotar; Anand Mehra; Anthony L D'Ambrosio; Bartosz T Grobelny; David L Penn; E Sander Connolly Journal: J Neurosci Methods Date: 2006-02-13 Impact factor: 2.390
Authors: Gabriel A Borges; Liana P Webber; Ana Elizia M Marques; Eliete Ns Guerra; Rogerio M Castilho; Cristiane H Squarize Journal: Regen Med Date: 2020-03-30 Impact factor: 3.806
Authors: Rui Liu; Jun-Chun Tang; Meng-Xian Pan; Yang Zhuang; Ya Zhang; Hua-Bao Liao; Dan Zhao; Yang Lei; Rui-Xue Lei; Shu Wang; An-Chun Liu; Xing-Ping Qin; Juan Chen; Zhi-Feng Zhang; Qi Wan Journal: Neurochem Res Date: 2018-06-07 Impact factor: 3.996